Houston, TX – November 01, 2011 - - (BUSINESS WIRE) ----- Hybrid Pharmaceutical, the Genomics Biotech Engineering company, today announced that Barron Graham’s – Graham is to join Hybrid GenNxeix Inc. (GenNxeix) as a Biotech Consulting Partner effective November 1, 2011. Barron will work directly with the Vice President of Worldwide Marketing in developing strategic marketing, branding, communications and sales initiatives for Hybrid GenNxeix ®. Mr. Graham bring more than 28years of expertise in brand management, business planning, advertising, digital, integrated communications, direct marketing, promotions, research and sales & marketing.
Barron brings a breath of experience and strong track record of leadership in successfully building brands and pioneering new markets,” said Rose Conrad Ph.D., Chief Executive Officer of Hybrid Pharmaceutical.
“His years of experience in developing go-to-market strategies, his intelligence and his excitement to become part of Hybrid GenNxeix is evident that Barron’s direction and steward of the GenNxeix brand will help to strengthen and solidify our market leadership position,” she said.
Hybrid GenNxeix a new subsidiary of Hybrid Pharma, is committed to being the world’s premiere Medical Informatics and Medical Services Companies. As a leader in genomic trials, healthcare IT, scientist electronic GenNxeix, development and manufacturing of biologics, the company offers a suite of products and services. Products and services include DNA paternity testing, Genomics analysis and testing, BioGenetic research and samples and Regenerative medicine.
As an entrepreneur for more than 28 years, Barron Graham’s unique qualifications in Business Establishment, Business Development and Marketing makes him highly capable and much sought after in the business world. His experience and expertise came from across section of industries namely: Real Estate, Investment Banking, Telecoms Retail, Business Financing, Insurance, Merchant Services, Network Marketing and Business Establishment & Development. In which he is personally starting more than 100 companies in several countries.
This press release contains forward-looking statements, including statements relating to the expected demand for Hybrid Pharma's products and services, statements regarding Hybrid Pharma’s growth and market opportunities, and statements relating to Hybrid Pharma’s ability to meet the needs of distributed organizations. These forward-looking statements involve risks and uncertainties, as well as assumptions that, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Hybrid Pharma reserves the right to modify future product plans at any time.
About Hybrid Pharma
Hybrid Pharma is a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services is available at GenNxeix.
“As you look around, you’ll see that medicine has changed dramatically. There is a huge Genomic shift occurring. The Genomicst has completely redefined the world’s economy and has created evidence base Medicine. If you are in medicine today and you are not using Genomics Science o, you will be left behind.”
No comments:
Post a Comment